Press release
Parkinson's disease psychosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment, Pipeline | Vanda Pharmaceuticals, Sumitomo Pharma
Parkinson’s disease psychosis Clinical Trials
DelveInsight reports that the Parkinson's disease psychosis pipeline includes over five key companies actively developing more than five investigational therapies.
Parkinson's disease psychosis Overview:
Nonmotor symptoms have a major impact on the quality of life of Parkinson's disease (PD) patients and their caregivers, and growing awareness among healthcare professionals highlights their significance. Psychosis is among the most common and debilitating nonmotor symptoms, affecting 20% to 70% of patients in advanced PD stages. It usually emerges in individuals with an intact sensorium during chronic disease progression and is often precipitated or exacerbated by medications. Recent research, however, points to additional risk factors, indicating a multifactorial origin and complex underlying mechanisms. The classification of early- versus late-onset psychosis, both generally and within PD, remains unstandardized, with some studies defining early-onset psychosis as occurring within 2-4 years of PD diagnosis.
Request for a detailed insights report on Parkinson's disease psychosis pipeline insights [https://www.delveinsight.com/report-store/parkinsons-disease-psychosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Parkinson's disease psychosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Parkinson's disease psychosis Therapeutics Market.
Key Takeaways from the Parkinson's disease psychosis Pipeline Report
*
DelveInsight's Parkinson's disease psychosis pipeline report highlights an active landscape, with over five companies developing more than five investigational therapies for the treatment of Parkinson's disease psychosis.
*
Leading companies in this space, including Vanda Pharmaceuticals, Sumitomo Pharma, and others, are advancing new drugs to enhance the treatment options for this condition. Promising pipeline candidates in various stages of development include Iloperidone, Ulotaront, and additional therapies.
*
AbbVie Inc. has been developing tavapadon, a selective D1/D5 receptor partial agonist, for early-stage Parkinson's disease. In December 2025, AbbVie reported positive outcomes from a third Phase 3 trial, showing notable improvements in motor function, and plans to pursue FDA approval later in 2025.
Parkinson's disease psychosis Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Parkinson's disease psychosis Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson's disease psychosis treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Parkinson's disease psychosis market.
Download our free sample page report on Parkinson's disease psychosis pipeline insights [https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Parkinson's disease psychosis Emerging Drugs
*
Iloperidone: Vanda Pharmaceuticals
*
Ulotaront: Sumitomo Pharma
Parkinson's disease psychosis Companies
Over five leading companies are actively working on therapies for Parkinson's disease psychosis, with Vanda Pharmaceuticals having a candidate in the most advanced stage, currently in Phase II clinical trials.
DelveInsight's report covers around 5+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Parkinson's disease psychosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Parkinson's disease psychosis Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Parkinson's disease psychosis Therapies and Key Companies: Parkinson's disease psychosis Clinical Trials and advancements [https://www.delveinsight.com/report-store/parkinsons-disease-psychosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Parkinson's disease psychosis Pipeline Therapeutic Assessment
- Parkinson's disease psychosis Assessment by Product Type
- Parkinson's disease psychosis By Stage
- Parkinson's disease psychosis Assessment by Route of Administration
- Parkinson's disease psychosis Assessment by Molecule Type
Download Parkinson's disease psychosis Sample report to know in detail about the Parkinson's disease psychosis treatment market @ Parkinson's disease psychosis Therapeutic Assessment [https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Parkinson's disease psychosis Current Treatment Patterns
4. Parkinson's disease psychosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Parkinson's disease psychosis Late-Stage Products (Phase-III)
7. Parkinson's disease psychosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Parkinson's disease psychosis Discontinued Products
13. Parkinson's disease psychosis Product Profiles
14. Parkinson's disease psychosis Key Companies
15. Parkinson's disease psychosis Key Products
16. Dormant and Discontinued Products
17. Parkinson's disease psychosis Unmet Needs
18. Parkinson's disease psychosis Future Perspectives
19. Parkinson's disease psychosis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Parkinson's disease psychosis Pipeline Reports Offerings [https://www.delveinsight.com/report-store/parkinsons-disease-psychosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=parkinsons-disease-psychosis-clinical-trials-companies-therapeutic-assessment-therapies-treatment-pipeline-vanda-pharmaceuticals-sumitomo-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's disease psychosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment, Pipeline | Vanda Pharmaceuticals, Sumitomo Pharma here
News-ID: 4155053 • Views: …
More Releases from ABNewswire
Amyotrophic Lateral Sclerosis Clinical Trials, Companies, Therapies, Pipeline | …
DelveInsight's, "Amyotrophic Lateral Sclerosis (ALS) - Pipeline Insight, 2025," report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis (ALS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
DelveInsight reports that the Amyotrophic Lateral Sclerosis (ALS) pipeline involves over 75 key companies actively developing…
Extensive-Stage Small Cell Lung Cancer (ESCLC) Clinical Trials, Companies, Thera …
DelveInsight's, "Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
DelveInsight reports that the Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline involves…
Primary Ciliary Dyskinesia Clinical Trials, Companies, Therapies, Pipeline | Par …
DelveInsight's, "Primary Ciliary Dyskinesia - Pipeline Insight, 2025," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Primary Ciliary Dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Primary Ciliary Dyskinesia Pipeline constitutes 4+ key companies…
Nucleic Acid and Gene Therapies in Neuromuscular Disorders Clinical, Companies, …
DelveInsight's, "PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
DelveInsight highlights that the Nucleic Acid and Gene Therapies pipeline…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.43 billion…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
